Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Clinical trial NCT02364609 · COMPLETED

Trial details

NCT number: NCT02364609
Sponsor: Jonathan Riess
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Non-Small Cell Lung Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer

Start date: 2015-09-30
Primary completion: 2018-04-26
Enrollment: 11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.